PRS

Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial

Retrieved on: 
星期日, 九月 10, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neutropenia, Brain, Central nervous system, PRS, HER3, Liver disease, American Journal of Clinical Oncology, TSE, DOR, DCR, Trastuzumab deruxtecan, Lung cancer, ILD, TKI, NSCLC, Treatment of lung cancer, History, Immunotherapy, CNS, PFS, Associate, Patritumab, ORR, Radiation, Journal, HIV disease progression rates, MD, EGFR, Patient, Leukopenia, Daiichi Sankyo, Anemia, Hypokalemia, DXD, Weakness, Memorial Sloan Kettering Cancer Center, ADC, CRS, Diagnosis, Neoplasm, R, Thrombocytopenia, SD, Conference, PR, Fatigue, Medical imaging, Fine chemical, Pharmaceutical industry

Results from the HERTHENA-Lung01 phase 2 trial showed that patritumab deruxtecan (HER3-DXd) demonstrated clinically meaningful and durable responses in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following disease progression with an EGFR TKI and platinum-based chemotherapy.

Key Points: 
  • Results from the HERTHENA-Lung01 phase 2 trial showed that patritumab deruxtecan (HER3-DXd) demonstrated clinically meaningful and durable responses in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following disease progression with an EGFR TKI and platinum-based chemotherapy.
  • Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s (TSE: 4568) proprietary DXd ADC technology.
  • One complete response (CR), 66 partial responses (PRs) and 99 cases of stable disease (SD) were seen.
  • As of the snapshot data cutoff of May 18, 2023, the median trial duration was 18.9 (14.9-27.5) months, and 13 patients were continuing to receive patritumab deruxtecan.

Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Retrieved on: 
星期日, 九月 10, 2023
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PRS, DCR, International Association, Lung cancer, ILD, NSCLC, Carboplatin, Lung, AstraZeneca, Alvin J. Siteman Cancer Center, HIV disease progression rates, MD, Patient, EGFR, DXD, Daiichi Sankyo, Anemia, Washington University School of Medicine, ADC, Spacecraft, Thrombocytopenia, ORR, Conference, TSE, Disease, ALK, Pharmaceutical industry, Fine chemical, Durvalumab

These data were presented today during a late-breaking oral presentation ( OA05.06 ) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23).

Key Points: 
  • These data were presented today during a late-breaking oral presentation ( OA05.06 ) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23).
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • Response rates were higher in patients receiving datopotamab deruxtecan plus durvalumab and carboplatin (triplet; n=13) which demonstrated an ORR of 76.9% (95% CI: 46.2-95.0), including 10 PRs and a DCR of 92.3% (95% CI: 64.0-99.8).
  • “The TROPION-Lung04 results offer preliminary evidence for the efficacy of datopotamab deruxtecan in combination with durvalumab and chemotherapy in first-line advanced non-small cell lung cancer with no new safety signals.

Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial

Retrieved on: 
星期日, 九月 10, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Learning, Carcinoma, Brain, PRS, TSE, DOR, COVID-19, Survival, Cancer, International Association, Lung cancer, ILD, Pneumonitis, Neoplasm, Appetite, Immunotherapy, PFS, SCLC, Vomiting, HIV disease progression rates, MD, Patient, DXD, Daiichi Sankyo, Anemia, Irinotecan, Nausea, ADC, Conference, ORR, Pneumonia, Fatigue, Taxane, Sarah Cannon Research Institute, Medical imaging, Pharmaceutical industry

Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer (SCLC).

Key Points: 
  • Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer (SCLC).
  • Ifinatamab deruxtecan is a specifically engineered potential first-in-class B7-H3 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s (TSE: 4568) proprietary DXd ADC technology.
  • “With limited effective treatment options beyond traditional chemotherapy and immunotherapy, small cell lung cancer can be difficult to treat,” said Melissa Johnson, MD, Director, Lung Cancer Research, Sarah Cannon Research Institute.
  • The median duration of follow up was 11.7 months (95% CI: 4.63-12.88) and two patients remain on treatment with ifinatamab deruxtecan.

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

Retrieved on: 
星期四, 八月 31, 2023
Bevacizumab, Senior, ADCC, Neoplasm, Lead, Head, Bioinformatics, GAAP, Information technology, Doctor of Philosophy, Patient, HNSCC, ADCP, Research and development, R, HCC, SAB, CD47, PRS, Therapy, Merck & Co., Net, Cervical cancer, CPS, MSI, ADC, PD-1, PR, Safety, Exercise, AACR, Liver disease, MSS, Roche, Therapeutic index, GenScript Biotech, American Association for Cancer Research, CR, Pembrolizumab, ORR, Renal cell carcinoma, SCC, CRC, RCC, ADS, CMC, Yan Li, Clinical trial, Trae Waynes, Endometrial cancer, Financial toxicity, Poster, Tumor microenvironment, Pharmaceutical industry, Palladium, Medical imaging, Vaccine, Management, Cryptocurrency, Fine chemical, Bank, Legend, Immunoglobulin G, MD, Sanofi, Exelixis

Additionally, Fangyong (Felix) Du, Ph.D, Chief Technology Officer at Adagene since 2020, is stepping down from the board for personal reasons.

Key Points: 
  • Additionally, Fangyong (Felix) Du, Ph.D, Chief Technology Officer at Adagene since 2020, is stepping down from the board for personal reasons.
  • Cash and cash equivalents were US$128.8 million as of June 30, 2023, compared to US$143.8 million as of December 31, 2022.
  • The company uses non-GAAP net loss and non-GAAP net loss per ordinary shares for the period, which are non-GAAP financial measures, in evaluating its operating results and for financial and operational decision-making purposes.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Ivalua's New Platform Release Accelerates AI-Powered Contract Digitization and Overall Purchasing Optimization

Retrieved on: 
星期二, 八月 29, 2023
Cloud, Spend, Digital card, CLM, PRS, Workflow, Procurement, AVL, Contract lifecycle management, OCR, Automatic identification and data capture, AML, Payment, Digital, Fraud, Automation, Cryptocurrency, Risk management, Medical device, Online shopping

REDWOOD CITY, Calif., Aug. 29, 2023 /PRNewswire/ -- Ivalua, a global leader in Cloud Spend Management solutions, announced the general availability of its new platform release 178. This release reflects Ivalua's growing investment in R&D, including a broad set of new innovations that improve contract digitization and analytics, enhance visibility to optimize disparate purchasing activities, extend global e-invoicing compliance, enable new virtual card payment scenarios and provide a built-in digital adoption layer.

Key Points: 
  • Refreshed contract analytics with updated reports covering contract approval cycle times, clause usage and deviations, and much more.
  • A new Purchasing Optimization Center brings a centralized view across all purchase requisition (PR) line items, enabling consolidation and efficiency.
  • "Our AI expertise and technology has come to fruition with Contract Lifecycle Management (CLM), Invoicing and more advancements to come soon.
  • Combined with customer-driven enhancements in purchasing optimization, virtual cards, and guided user enablement further demonstrate our focus on delivering innovations that unlock tangible value for our customers."

Guitar Center Partners with Eric Clapton, Carlos Santana and Leading Guitar Manufacturers on New Crossroads Guitar Festival's 25th Anniversary Guitar Collection

Retrieved on: 
星期五, 八月 25, 2023
Crypto.com, Village, Partnership, Guitar, Guitar Center, 58957: The Bluegrass Guitar Collection, Crossroads Guitar Festival, Education, Lenny, PRS, Crypto.com Arena, PRS Guitars, PDT, History, Person, EDT, Movement, Sale, Crossroads Centre, Collection, LOS, CREAM, Fender Eric Clapton Stratocaster, Family, Limited Edition, Music, Entertainment, Industrial design, L.A

LOS ANGELES, Aug. 24, 2023 /PRNewswire-PRWeb/ -- Guitar Center, the world's largest musical instrument retailer, in partnership with Eric Clapton, today announces the launch of the Crossroads Guitar Festival's 25th Anniversary Guitar Collection. This collection includes six limited-edition meticulously crafted recreations and signature guitars – several from Clapton's career and one from fellow guitarist Carlos Santana, along with some all-new signature models. These guitars will be sold in North America exclusively at Guitar Center locations and online via GuitarCenter.com beginning August 24.

Key Points: 
  • "On the occasion of the 2023 Crossroads Guitar Festival, Guitar Center is proud to once again show our support for Eric Clapton, the festival and his Crossroads Centre Antigua," said Michael Doyle, General Manager, Guitars, at Guitar Center.
  • The 2023 Crossroads Collection is the result of a unique and significant history between Guitar Center and Clapton and continues in the spirit of the first Eric Clapton Crossroads Guitar, originally offered in 2005.
  • "On the occasion of the 2023 Crossroads Guitar Festival, Guitar Center is proud to once again show our support for Eric Clapton, the festival and his Crossroads Centre Antigua," said Michael Doyle, General Manager, Guitars, at Guitar Center.
  • For more information and videos featuring the 2023 Crossroads Guitar Festival's 25th Anniversary Guitar Collection, please visit https://www.guitarcenter.com/Crossroads.gc .

Wolters Kluwer receives a record 8 Grand Awards in 2023 APEX Awards

Retrieved on: 
星期二, 八月 22, 2023
Technology, Mobile, Wireless, Health, Accounting, Professional Services, Publishing, Practice Management, Software, Networks, General Health, Data Analytics, Communications, Data Management, Nursing, Emergency medicine, PRS, Multimedia, The Nurse Practitioner: The American Journal of Primary Healthcare, Nurse educator, Grand Award Records, Nurse practitioner, Wolters Kluwer, APEX, American Journal of Nursing, News, Social media, Lippincott

Wolters Kluwer Health today announced that 15 of its Lippincott healthcare titles received 28 wins in the 35th annual Awards for Publication Excellence (APEX) Competition.

Key Points: 
  • Wolters Kluwer Health today announced that 15 of its Lippincott healthcare titles received 28 wins in the 35th annual Awards for Publication Excellence (APEX) Competition.
  • Seven of these titles received the prestigious Grand Awards including PRS Global Open, Neurology Today, Nurse Educator, The Nurse Practitioner, American Journal of Nursing, Nursing Management, and Emergency Medicine News.
  • For the 2023 program more than 1,100 nominations were received and only 100 Grand Award Winners were selected.
  • Grand Awards honor outstanding works in each main category, while Awards of Excellence recognize exceptional entries in each of the individual sub-categories.

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Retrieved on: 
星期三, 八月 16, 2023
Surgeon, PRS, Anatomy, Weakness, Permeability, Patient, University of Rochester Medical Center, 3D printing, Dentistry, MD

OviTex PRS Long-Term Resorbable is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.

Key Points: 
  • OviTex PRS Long-Term Resorbable is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
  • OviTex PRS Long-Term Resorbable supplements the Company's existing OviTex PRS portfolio, which includes OviTex PRS Permanent and OviTex PRS Short-Term Resorbable configurations.
  • OviTex PRS Long-Term Resorbable enhances the OviTex PRS portfolio with specific design features, including bi-directional stretch and a fully resorbable, long-term polymer for reinforcement.
  • “We are excited to offer expanded clinical utility of the OviTex PRS portfolio to surgeons and patients in plastic and reconstructive surgery,” said Antony Koblish, President and CEO of TELA Bio.

Broadwind Announces Second Quarter 2023 Results

Retrieved on: 
星期一, 八月 14, 2023
Acceleration, Yoy, Maintenance, PRS, GAAP, Steel, Wind, Inflation, EBITDA, CG Power and Industrial Solutions, Investment, Mining, Appendix, Growth, Inflation Reduction Act of 2022, Hand, Rare-earth element, Cardboard, Bank, Pharmaceutical industry, Renewable energy, Video game, CICERO

CICERO, Ill., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Broadwind, Inc. (Nasdaq: BWEN, “Broadwind” or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the second quarter 2023.

Key Points: 
  • CICERO, Ill., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Broadwind, Inc. (Nasdaq: BWEN, “Broadwind” or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the second quarter 2023.
  • The Company reported GAAP net income of $1.4 million, or $0.07 per diluted share, in the second quarter 2023, compared to a net loss of ($2.7) million, or ($0.13) per basic share, in the second quarter 2022.
  • As of June 30, 2023, Broadwind had total cash on hand and availability under its credit facility of $15.2 million, as compared to $10.2 million at the end of the second quarter 2022.
  • Non-GAAP adjusted EBITDA increased meaningfully on a year-over-year basis across each reporting segment during the second quarter of 2023.

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

Retrieved on: 
星期三, 八月 16, 2023
PRS, American Society of Clinical Oncology, CSPC, Assistant, Shijiazhuang Pharma Group, HKEX, Patient, Annual general meeting, ADC, Stomach, Society, Safety, Sarah Cannon Research Institute, Medical imaging, Pharmaceutical industry, MSCI

"The dosing of the first patient is a major milestone in evaluating EO-3021's potential benefit for these patients," said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology.

Key Points: 
  • "The dosing of the first patient is a major milestone in evaluating EO-3021's potential benefit for these patients," said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology.
  • CSPC Pharmaceutical Group Limited (HKEX: 01093), is also evaluating SYSA1801 (EO-3021) in an ongoing Phase 1 clinical trial in China (NCT05009966).
  • Preliminary data from CSPC's Phase 1 study were presented at the American Society of Clinical Oncology 2023 Annual Meeting.
  • Elevation Oncology has licensed the exclusive rights to develop and commercialize EO-3021 in all global territories outside Greater China from CSPC.